As such, external partnerships are highly encouraged not only as a funding leverage but to bring innovative ideas and approaches into human exploration programs. These solicitations encourage use of collaborations to ensure maximum benefit to both the space program and the nation. The program also provides a platform to continue to grow and maintain critical skills and innovations needed to ensure future mission success. It offers the center the ability to address technology gaps that are beyond the requirements of near-term programs to fund. The JSC-directed solicitations program enables the center to invest strategically in high priority areas needed to accomplish future missions, as articulated in the NASA Technology Roadmaps and the Space Technology Investment Plan (STIP). An active and sustainable science and technology development program is key to ensuring the challenges of human exploration are successfully overcome. The center encourages collaboration with aerospace and non-aerospace industries, government agencies, and academia to solve science and technology challenges, while actively striving to maximize technology transfer into the commercial sector. All Claritas are fully compliant with HIPPA, PDPA and GDPR requirements.JSC provides and applies its preeminent capabilities in science and technology to develop, operate, and integrate human exploration missions.
#Irad technology software#
Claritas aims to transform the diagnostics industry with powerful and effective software products created using image enhancement and AI technology enabling and assisting doctors and physicians to make accurate diagnosis and improve patient lives. Paul added, “ The evaluation of iRAD TM using the NCCID could deliver benefits for patients and clinicians in multiple parts of the health ecosystem from screening programmes, A&E to complex intervention planning.”Ĭlaritas conducts research and development in the fields of image enhancement, machine vision and artificial intelligence (“AI”) with a focus on medical image processing and AI assisted interpretation and diagnostics.
The parameters under assessment will include the optimisation of technical image quality, improvements in clinician interpretation, lesion identification and the potential of these enhanced data sets to train more accurate AI tools to further support clinicians and improve patient safety.ĭr. Arup Paul, Chief Clinical Strategy Officer at Claritas. “ Recognising the need to evaluate the performance of new technologies with data representative of the population and by clinicians delivering that care, Claritas has designed a study to evaluate the benefits of iRAD TM with data that is representative of that population,” commented, Dr. The study will evaluate data across modalities (X-Rays, CT, and MRI) using multiple clinical, operational, and quality parameters for the benefit of patient outcomes. 24, 2022 (GLOBE NEWSWIRE) - Claritas HealthTech (“Claritas”), a healthcare technology company specializing in medical image enhancement and Artificial Intelligence (AI) assisted diagnostic tools, announces today that it has been awarded access to the National Covid-19 Chest Imaging Database (NCCID) curated by the AI Lab NHSE, after a rigorous and peer-reviewed assessment process to evaluate the benefits of iRAD TM across modalities and conditions.Ĭlaritas will carry out research using iRAD TM, its image enhancement Software as a Medical Device (SaMD), with leading UK-based consultant Radiologists.
0 kommentar(er)
